---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-24-000018"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2024-05-03T23:59:59+00:00"
generated_at: "2026-06-02T23:13:30.582230+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Amneal Q1 revenue $659M (+18% YoY); GAAP net loss $92M on $94M opioid charge

## Summary
- Net revenue $659M (+18% YoY); Generics +14%, Specialty +15%, AvKARE +33%.
- GAAP net loss $92M ($0.30 loss per share) includes $94M pre-tax charge for nationwide opioids settlement in principle.
- Adjusted EBITDA $152M (+31% YoY); adjusted diluted EPS $0.14 (vs $0.12 YoY).
- Opioids settlement payable over ten years; company affirming 2024 full-year guidance.
- All three segments posted double-digit revenue growth for first time in same quarter.

## SEC filing metadata
- accession: 0001723128-24-000018
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2024-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000018/0001723128-24-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000018/amrx-20240503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-24-000018
- JSON: https://secwatch.observer/filing/0001723128-24-000018.json
- Plain text: https://secwatch.observer/filing/0001723128-24-000018.txt

## Key facts
- Earnings Releases
  Amneal Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: revenue $659 million, net income $92 million, EPS $0.30. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2024
  - Revenue: $659 million
  - Net income: $92 million
  - EPS: $0.30
  - Guidance: reaffirmed
  - Result: reported results
  source text: the information furnished pursuant to Item 2.02 of this report. --- EX-99.1 (EX-99.1) --- AMNEAL REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS ‒ Q1 2024 Net Revenue of $659 million; GAAP Net Loss of $92 million; Diluted Loss per Share of $0.30 ‒ ‒ Adjusted EBITDA of $152 million; Adjusted Diluted EPS of $0.14 ‒ ‒ Company has reached settlement in principle
  evidence_url: https://www.sec.gov/Archives/edgar/data/1723128/000172312824000018/0001723128-24-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.